← All trials
NCT07272434
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2025
- Primary completion
- Jul 31, 2026
- Completion date
- Dec 31, 2028
- First posted
- Dec 9, 2025
- Last posted
- Dec 9, 2025
- Enrollment
- 25000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MAXVAX Biotechnology Limited Liability CompanyLead sponsor
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaOfficial
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.